Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure.
Vessel dilator and kaliuretic hormone, two cardiovascular peptide hormones, enhance urine flow 2- to 13-fold and 4-fold, respectively, in persons with class III New York Heart Association congestive heart failure (CHF). The natriuresis and diuresis secondary to vessel dilator and kaliuretic hormone are not blunted as are atrial natriuretic peptide and brain natriuretic peptide effects in persons with CHF compared with healthy individuals. The present investigation determined if the two peptide hormones that do not have blunted effects in persons with CHF may have added beneficial effects when given simultaneously to individuals with class III CHF. Together with each at 100 ng/kg of body weight per minute, vessel dilator and kaliuretic hormone increased urine flow rate 3.5-fold (P < 0.05) compared with their 60-min baseline and control CHF subjects' urine flow rates. Combined, they enhanced the excretion rate of sodium a maximum of 3.6-fold (P < 0.05) with 2.5- and 2-fold enhancement 2 and 3 hrs after infusion. These data indicate that vessel dilator and kaliuretic hormone have diuretic and natriuretic effects when used in combination, but these effects are not additive over their individual effects in persons with CHF.
Patel
Hamang
H
U.S.F. Cardiac Hormone Center, Department of Medicine, University of South Florida Health Sciences Center, and Medicine and Pharmacy Services, James A. Haley Veterans Medical Center, Tampa, Florida 33612, USA.
Dietz
John R
JR
Owen
Ashley
A
San Miguel
Gloria
G
McCormick
Michael T
MT
Schocken
Douglas D
DD
Vesely
David L
DL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D016022:Case-Control Studies; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D011188:Potassium / Q000097:blood / Q000652:urine; D011498:Protein Precursors / Q000008:administration & dosage* / Q000494:pharmacology; D012964:Sodium / Q000097:blood / Q000652:urine; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D014563:Urodynamics / Q000187:drug effects
D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D011498:Protein Precursors; C075322:atrial natriuretic factor precursor (79-98); C054548:atrial natriuretic factor prohormone (31-67); D009320:Atrial Natriuretic Factor; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D011188:Potassium